Xofluza (baloxavir marboxil) — CareFirst (Caremark)
Post-exposure prophylaxis of influenza in persons age ≥ 5 years following contact with an individual who has influenza
Preferred products
- Relenza (zanamivir)
- Tamiflu (oseltamivir)
Initial criteria
- Authorization may be granted when the requested drug is being prescribed for treatment of acute uncomplicated influenza in a patient age ≥ 5 years who is otherwise healthy or at high risk for influenza-related complications and symptomatic ≤ 48 hours OR for post-exposure prophylaxis of influenza in a patient age ≥ 5 years after contact with an infected individual
Approval duration
3 months